Skip to main content
. 2024 Jul 29;39(10):1393–1405. doi: 10.1093/jbmr/zjae119

Figure 4.

Figure 4

Probability of attaining T-score above −2.5 for TH (A) and LS (B) over 3 yr during treatment with alendronate, romosozumab followed by alendronate, or romosozumab followed by denosumab, based on starting T-score.39